Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ARG1 | P05089 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3547824 | 1.00 | MAPK1 (0.32) | MAPK1ARG1RECQLNFKB1NFKB2 | |
| SCHEMBL3547827 | 1.00 | MAPK1 (0.32) | MAPK1ARG1RECQLNFKB1NFKB2 | |
| SCHEMBL23394417 | 0.83 | ARG1 (0.34) | MAPK1ARG1 | |
| SCHEMBL30557090 | 0.83 | ARG1 (0.34) | MAPK1ARG1 | |
| SCHEMBL12909511 | 0.77 | MAPK1 (0.39) | MAPK1RECQL | |
| SCHEMBL20146370 | 0.77 | MAPK1 (0.39) | MAPK1RECQL | |
| Hydrochloric Acid SCHEMBL28928210 | 0.76 | MAPK1 (0.38) | MAPK1RECQL | |
| SCHEMBL11015981 | 0.74 | — | — | |
| SCHEMBL5728913 | 0.72 | MAPK1 (0.37) | MAPK1RECQLNFKB1NFKB2RELA | |
| SCHEMBL27571195 | 0.72 | ARG1 (0.34) | MAPK1ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | AMDHD2, OGA, ENGASE | MAPK1 3387/4885ARG1 2243/4885RECQL 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.